NCT03590574 - Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

December 12, 2024

Study Completion Date

December 12, 2024

Conditions

T Cell Non-Hodgkin LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaAnaplastic Large Cell Lymphoma

Interventions

BIOLOGICAL

AUTO4

AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10\^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.

Trial Locations (5)

Unknown

Vall d'Hebron Institute of Oncology, Barcelona

Queen Elizabeth University Hospital, Glasgow

University College London Hospitals NHS Foundation Trust, London

Manchester Royal Infirmary Hospital, Manchester

Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors

lead

Autolus Limited

INDUSTRY